(Q38670952)

English

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

scientific article published on 04 December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

1 reference

based on heuristic

inferred from title

object named as

Cristina Joao

9

0 references

Wojciech Jurczak

object named as

Wojciech Jurczak

2

0 references

Mathias Witzens-Harig

object named as

Mathias Witzens-Harig

10

0 references

object named as

Marek Trneny

6

0 references

0 references

3

object named as

Mats Jerkeman

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

author name string

Martin Dreyling

1

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Rodrigo Santucci Silva

4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Chiara Rusconi

5

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Fritz Offner

7

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Dolores Caballero

8

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Georg Hess

11

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Isabelle Bence-Bruckler

12

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Seok-Goo Cho

13

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

John Bothos

14

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Jenna D Goldberg

15

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Christopher Enny

16

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Shana Traina

17

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sriram Balasubramanian

18

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Nibedita Bandyopadhyay

19

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Steven Sun

20

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Jessica Vermeulen

21

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Aleksandra Rizo

22

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Simon Rule

23

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

language of work or name

0 references

publication date

4 December 2015

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

387

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

10020

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

770-778

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The current therapeutic scenario for relapsed mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the investigation and management of mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Colonel Bruton's kinase defined the molecular basis of X-linked agammaglobulinemia, the first primary immunodeficiency.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Bruton tyrosine kinase (BTK) and its role in B-cell malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2900667-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(15)00667-4

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38670952&oldid=1773748540"